Diagnosis and treatment of nonalcoholic fatty liver disease in patients with metabolic syndrome: potential of cardiac and antidiabetic medications
https://doi.org/10.21518/2079-701X-2014-11-66-69
Abstract
According to recent guidelines of AASLD, AGA and ACG, NAFLD is a liver disease accompanied by the accumulation of fatty acid content greater than 5% of hepatocytes weight, absence of substantial alcohol consumption (20 g per day for men, 10 g per day for women), absence of hepatitis viruses and other specific causes of liver disease.
Keywords
НАЖБП,
метаболический синдром,
ожирение,
орлистат,
аторвастатин,
Липтонорм,
NAFLD,
metabolic syndrome,
obesity,
orlistat,
atorvastatin,
Liptonorm
About the Authors
S. V. Nedogoda
Volgograd State Medical University
Russian Federation
Russian Federation
T. N. Sanina
Volgograd State Medical University
Russian Federation
Russian Federation
T. A. Chalyabi
Volgograd State Medical University
Russian Federation
Russian Federation
I. N. Barykina
Volgograd State Medical University
Russian Federation
Russian Federation
V. V. Tsoma
Volgograd State Medical University
Russian Federation
Russian Federation
E. V. Chumachek
Volgograd State Medical University
Russian Federation
Russian Federation
A. S. Salasyuk
Volgograd State Medical University
Russian Federation
Russian Federation
V. Y. Khripaeva
Volgograd State Medical University
Russian Federation
Russian Federation
V. O. Smirnova
Volgograd State Medical University
Russian Federation
Russian Federation
Review
For citations:
Nedogoda SV, Sanina TN, Chalyabi TA, Barykina IN, Tsoma VV, Chumachek EV, Salasyuk AS, Khripaeva VY, Smirnova VO. Diagnosis and treatment of nonalcoholic fatty liver disease in patients with metabolic syndrome: potential of cardiac and antidiabetic medications. Meditsinskiy sovet = Medical Council. 2014;(11):66-69. (In Russ.) https://doi.org/10.21518/2079-701X-2014-11-66-69
Views:
415
Email this article 